Axsome Therapeutics Target Price

See Axsome Therapeutics's analyst price targets ($300) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$220.75

Average Target Price

$295.22

33.7% upside

9 analysts in the last 4 months

High: $380 | Low: $251

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-12	Mizuho SecuritiesGraig Suvannavejh	$316	43.1% upside
2026-08-11	RBC CapitalLeonid Timashev	$297	34.5% upside
2026-08-11	Morgan Stanley	$251	13.7% upside
2026-08-11	NeedhamAmi Fadia	$268	21.4% upside
2026-08-11	Guggenheim	$275	24.6% upside
2026-08-11	Wells Fargo	$256	16% upside
2026-07-20	BMO CapitalMalcolm Hoffman	$310	40.4% upside
2026-07-07	RBC CapitalLeonid Timashev	$304	37.7% upside
2026-06-11	JefferiesAndrew Tsai	$380	72.1% upside
2026-05-05	Deutsche BankDavid Hoang	$280	26.8% upside
2026-05-05	Morgan Stanley	$242	9.6% upside
2026-05-05	Needham	$267	21% upside
2026-05-05	RBC CapitalLeonid Timashev	$302	36.8% upside
2026-05-05	Robert W. BairdBrian Skorney	$246	11.4% upside
2026-05-05	H.C. Wainwright	$290	31.4% upside
2026-05-04	Oppenheimer	$280	26.8% upside
2026-05-04	GuggenheimYatin Suneja	$260	17.8% upside
2026-05-04	Piper Sandler	$258	16.9% upside
2026-05-04	Cantor Fitzgerald	$272	23.2% upside
2026-05-04	JefferiesAndrew Tsai	$275	24.6% upside
2026-05-04	Deutsche BankDavid Hoang	$281	27.3% upside
2026-05-04	H.C. WainwrightRaghuram Selvaraju	$270	22.3% upside
2026-05-01	Oppenheimer	$250	13.3% upside
2026-04-30	Morgan Stanley	$217	1.7% downside
2026-04-10	UBS	$259	17.3% upside
2026-02-24	RBC Capital	$222	0.6% upside
2026-02-24	UBS	$251	13.7% upside
2026-02-24	Morgan Stanley	$207	6.2% downside
2026-02-24	Guggenheim	$220	0.3% downside
2026-02-24	Wells Fargo	$202	8.5% downside
2026-02-23	Wolfe ResearchRudy Li	$230	4.2% upside
2026-02-23	Truist FinancialJoon Lee	$200	9.4% downside
2026-02-23	Jefferies	$215	2.6% downside
2026-02-19	Mizuho Securities	$230	4.2% upside
2026-01-21	RBC CapitalLeonid Timashev	$219	0.8% downside
2026-01-20	H.C. Wainwright	$260	17.8% upside
2026-01-16	Piper Sandler	$223	1% upside
2026-01-13	Robert W. Baird	$209	5.3% downside
2026-01-13	Wells Fargo	$193	12.6% downside
2026-01-08	Morgan Stanley	$204	7.6% downside
2026-01-06	UBS	$248	12.3% upside
2026-01-05	NeedhamAmi Fadia	$225	1.9% upside
2026-01-05	H.C. WainwrightRaghuram Selvaraju	$200	9.4% downside
2026-01-02	GuggenheimYatin Suneja	$205	7.1% downside
2025-12-31	Mizuho SecuritiesGraig Suvannavejh	$217	1.7% downside
2025-12-31	OppenheimerJay Olson	$220	0.3% downside
2025-11-04	H.C. Wainwright	$185	16.2% downside
2025-11-04	RBC Capital	$198	10.3% downside
2025-11-04	Morgan Stanley	$196	11.2% downside
2025-11-04	Wells Fargo	$157	28.9% downside

Axsome Therapeutics (AXSM) FAQ

Axsome Therapeutics (AXSM) currently reports a target price of $300. Use the charts on this page to explore Axsome Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Axsome Therapeutics is $300, about 33.7% upside from the current share price of $220.75. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $300, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Axsome Therapeutics, and consider following AXSM for alerts when major investors trade the stock.

Axsome Therapeutics is classified in the Healthcare sector. On target price, it currently shows $300. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AXSM with unrelated industries.